Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

Core Insights - Calliditas Therapeutics will present data and host a symposium at the 61st European Renal Association Congress in Stockholm from May 23-26, 2024, focusing on Nefecon's efficacy in treating primary immunoglobulin A nephropathy (IgAN) [1][2] Company Information - Calliditas is headquartered in Stockholm and has developed the first treatment specifically designed for IgAN, addressing a significant unmet need in this rare disease [2] - The company is actively engaging with leaders in the renal space to highlight the potential of its treatment [2] Presentation Details - The oral poster presentation titled "Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan" is scheduled for May 25, 2024, from 3:15-4:30 CET [3] - A poster presentation on "Real-world challenges associated with the use of systemic glucocorticoids in a US IgAN cohort" will take place on May 26, 2024, from 8:54-9:06 CET [3] - A symposium titled "Clinical Markers in IgA Nephropathy: Is All Proteinuria the Same?" will be moderated by Prof. Jonathan Barratt on May 25, 2024, from 10:15-11:15 am [3][4] Product Information - TARPEYO is indicated for reducing kidney function loss in adults with IgAN who are at risk for disease progression [5] - TARPEYO is an oral 4mg delayed-release formulation of budesonide, designed to target mucosal B-cells in the ileum, which are involved in the pathogenesis of IgAN [14][15]